|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Why are mutation rates in epidermal growth factor receptor (EGFR) and erb-b2 receptor tyrosine kinase 2 (ERBB2) higher in lung cancer from never smokers than that from smokers?Question 62.
|
28974261 |
2017 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We reviewed our experience with non-smokers who had CLL and subsequently developed lung carcinoma, in an effort to better understand the clinical course of these patients, and to evaluate the role of HER-2/neu overexpression.
|
11679181 |
2001 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We report the effect of heregulin beta1, the ligand for erbB-3 and erbB-4 receptors, on the regulation of vascular endothelial growth factor (VEGF) expression, using a panel of breast and lung cancer cell lines with constitutive erbB-2 overexpression or engineered to stably overexpress the erbB-2 receptor.
|
10918604 |
2000 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib.
|
26559459 |
2015 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have determined the average gene copy numbers (AGCN) of the erbB-1 gene, encoding the epidermal growth factor receptor (EGF-R), the erbB-2 and the erbB-3 genes in breast, ovarian, oral, and lung cancer tissue by using double-differential PCR (ddPCR).
|
7607571 |
1995 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined changes in CTC numbers and morphology early after targeting therapy in EGFR-mutated PC-9 human lung cancer and HER2-gene amplified GLM-1 gastric cancer mouse CTC models using a cytology-based semi-automated CTC detection platform.
|
31519570 |
2019 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
We analyzed mutations in EGFR, KRAS, TP53, and ERBB2 in 198 surgically resected lung cancer specimens.
|
18334834 |
2008 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate the potential role of the c-erbB-2/neu gene in lung cancer metastasis systematically, we introduced the human c-erbB-2/neu gene into very low p185neu-expressing NCI-H460 human non-small cell lung cancer cells and then examined the experimental metastatic potentials among the parental NCI-H460 cells and stable transfectants with increased expression of p185neu.
|
7911396 |
1994 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
To assess antigen reactivity, <sup>89</sup>Zr-DFO-trastuzumab was evaluated using the Lindmo method and tested in PET/CT imaging of mouse models of human epidermal growth factor receptor 2-positive or -negative lung cancer.
|
30442753 |
2019 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, we conclude that systemic delivery of Ad.E1A(+) can efficiently achieve therapeutic effect in HER-2/neu-overexpressing lung cancer in vivo.
|
8875978 |
1996 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
This trial will provide information on whether T-DM1 monotherapy is effective against HER2+ lung cancer.
|
27497829 |
2017 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This is the first radiogenomics study of HER2 mutations in lung cancer.
|
29906786 |
2018 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, we tested for possible aberrations of the c-erbB-2 gene in the region of the transmembrane domain in surgical specimens of human primary lung cancer from 190 patients, and also examined 24 metastases and 26 specimens of noncancerous portions of the lung of the same patients.
|
1483946 |
1992 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
|
29532558 |
2018 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Z<sub>HER2:V2</sub>-pemetrexed conjugate could inhibit tumor growth of HER2-positive lung adenocarcinoma and may have the potential to become a targeted drug for lung cancer.
|
30578135 |
2020 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The variable responses to anti-HER2 therapies in these patients prompt us to examine impact of <i>HER2</i> variants and co-mutations on responses to anti-HER2 treatments in lung cancer.
|
31748336 |
2019 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this was to see whether the ERBB2 kinase domain is mutated in other lung cancer types besides the adenocarcinoma.
|
16029927 |
2006 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The present study involves ligand-based pharmacophore modeling of various kinases, including EGFR (T790 M), cMET, ErbB2, FGFR and ALK, which are well established targets of normal as well resistant lung cancer.
|
30343450 |
2018 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The pooled data showed that HER2 overexpression was a marker of poor prognosis in lung cancer.
|
21155183 |
2010 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The peptidomimetic (Cyclo(1,10)PpR (<i>R</i>) Anapa-FDDF-(<i>R</i>)-Anapa)R, compound 18) was shown to exhibit antiproliferative activity with an IC<sub>50</sub> of 194 nM in HER2-expressing breast cancer cell lines and 18 nM in lung cancer cell lines.
|
29088782 |
2017 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The molecular target drugs for lung cancer with anaplastic lymphoma kinase (ALK) gene translocation (the fusion gene, EML4-ALK) was approved, and those targeting lung cancers addicted ROS1, RET, and HER2 have been under development.
|
27686809 |
2016 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The frequencies of HLA B35, B52, B62, DRB1*0404, and DRB1*0406 were higher in the ErbB-2-positive lung cancer patients than in the ErbB-2-negative lung cancer patients.
|
10754210 |
2000 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The excellent pharmacokinetic profiles of 19a in mice and rats led us to further investigation of a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast/gastric cancer and HER-2-mutated lung cancer.
|
22372864 |
2012 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The data presented herein suggest that the expression of HER2 did not influence the SM-induced apoptosis of different types of lung cancer cells and that the SM up-regulation of HER2 and TOP2A expressions simultaneously augmented trastuzumab and epirubicin-induced deaths of lung cancer H661 and H69 cells.
|
18078328 |
2008 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The biologic characteristics of the two human giant-cell lung carcinoma strains with high (strain D) and low metastatic potential (strain C) were studied, including karyotype of chromosome, intracellular free calcium ([Ca2+]i), morphologic changes of cell surface and the expression of nm23-H1, p53, ras, c-myc, c-erbB2, bcl-2 genes and PCNA.
|
10219898 |
1998 |